Skip Navigation LinksHome > March 2014 - Volume 347 - Issue 3 > Different β-Blockers and Initiation Time in Patients Undergo...
American Journal of the Medical Sciences:
doi: 10.1097/MAJ.0b013e31828c607c
Review Article

Different β-Blockers and Initiation Time in Patients Undergoing Noncardiac Surgery: A Meta-analysis

Dai, Neng MD; Xu, DaChun MD, PhD; Zhang, Ji MD; Wei, YiDong MD, PhD; Li, WeiMing MD; Fan, Bing MD; Xu, YaWei MD, PhD

Collapse Box

Abstract

The effects of differences among β-blockers and initiation times in patients undergoing noncardiac surgery (NCS) remain unknown. On June 1, 2012, the authors searched PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials to identify all trials of perioperative β-blockers in patients undergoing NCS published between January 1960 and June 2012. The authors included only randomized, double-blind and placebo-controlled trials of perioperatively administered β-blockers (ie, during the pre-, intra- and/or postoperative period) in patients with at least 1 risk factor for coronary artery disease undergoing NCS. The endpoints of these trials had to include all-cause mortality, myocardial infarction (MI) and/or stroke. The authors identified 8 English-language publications, involving 11,180 patients, which fulfilled our inclusion criteria. Perioperative β-blocker therapy was associated with a significant decrease in patient risk of developing MI (relative risk [RR] = 0.73; 95% confidence interval [CI], 0.61–0.86) but a significant increase in risk of developing stroke (RR = 2.17; 95% CI, 1.35–3.50) versus placebo, resulting in a nonsignificant decrease in overall mortality (RR = 0.91; 95% CI, 0.60–1.36). Indirect comparisons demonstrated that perioperative atenolol therapy was associated with lower mortality and incidence of MI. β-blocker therapy initiated >1 week before surgery was associated with improved postoperative mortality. Perioperative β-blocker treatment of patients undergoing NCS increases the incidence of stroke but decreases the incidence of MI, leading to a nonsignificant decrease in mortality. The authors also observed that atenolol treatment or β-blocker therapy initiated >1 week before NCS was associated with improved outcomes.

Copyright © 2013 by the Southern Society for Clinical Investigation

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.